Work

Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-14-0570

Authors: Toshio Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, Anthony W. Tolcher

Institutions: South Texas Accelerated Research Therapeutics, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Curis (United States)

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2166431958

FWCI: 2.555

Cites: 22

Cited by: 83

Related to: 10